Target intelligence / Profile preview

UDP-glucuronosyltransferase 2B15 (UGT2B15)

Target
UGT2B15
Molecular classification
Enzyme, Glycosyltransferase, Phase II drug-metabolizing enzyme
01

Overview

UDP-glucuronosyltransferase 2B15 (UGT2B15) is an enzyme primarily responsible for the glucuronidation of a wide range of endogenous and exogenous compounds, including steroid hormones (such as testosterone and estradiol), many drugs, and various environmental xenobiotics. By conjugating lipophilic substrates with glucuronic acid, UGT2B15 transforms them into more water-soluble metabolites, aiding in their elimination via urine or bile. UGT2B15 plays a key role in drug detoxification, hormone homeostasis, and protection against toxic exposures, and genetic variants in this enzyme contribute to interindividual differences in drug efficacy and safety. Alterations in UGT2B15 expression or function have been implicated in diseases such as cancer (breast, prostate), mood disorders, and others where steroid metabolism is relevant.

Other names
UDP-glucuronosyltransferase 2B8UGT2B8UDPGT 2B15UDPGT 2B8HLUG4UDPGTh-3UDPGTH3Uridine diphosphate glucuronosyltransferase 2 family, member B8Uridine diphosphate glycosyltransferase 2 family, member B15UDP glycosyltransferase 2B15EC 2.4.1.17
02

Mechanism of action

Catalysis of glucuronidation, conjugating drugs or endogenous substrates with glucuronic acid, increasing water solubility and facilitating renal or biliary excretion

03

Biological functions

Metabolism and elimination of toxic compounds (endogenous and xenobiotic)Regulation of steroid hormones (androgens, estrogens)Phase II metabolism (glucuronidation)Drug detoxification
04

Disease associations

Cancer (including breast and prostate cancer)Major depressive disorderAnxietyHormone-dependent diseases
05

Safety considerations

Genetic polymorphisms affecting enzyme activity and drug metabolism rate, leading to variation in drug response and risk of adverse drug reactions
06

Interacting drugs

Oxazepam

8 more in the full profile.

07

Biomarkers

UGT2B15 polymorphisms (e.g., D85Y variant) as biomarkers for interindividual differences in drug metabolism and hormone regulation, relevant in oncology and psychopharmacology

Beyond the preview

Go deeper on UDP-glucuronosyltransferase 2B15 (UGT2B15).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UDP-glucuronosyltransferase 2B15 (UGT2B15).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call